4 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Advanced Immunization Technologies (ADITEC)
Date du début: 1 oct. 2011, Date de fin: 30 sept. 2017,
Vaccines so far have been developed mostly by following an empiric approach. To prevent and possibly cure unresolved and emerging infectious diseases we need to fully exploit the potential of the human immune system. Progress in science and technology makes it possible to achieve what was previously deemed impossible. The scope of this project is to produce knowledge necessary to develop novel and ...
Voir le projet
53
Participants partenaires
TERMINÉ
Vaccination against Shigella and ETEC: novel antigens, novel approaches (STOPENTERICS)
Date du début: 1 nov. 2010, Date de fin: 30 avr. 2017,
To contribute to the development of vaccines against Shigella and ETEC for children of the developing world, STOPENTERICS will provide novel solutions by imposing a two-fold paradigm switch: (i) to break the dogma of serotype-specificity by inducing a cross-protective immunity (ii) to improve the immunogenicity of Shigella glycoconjugates by using synthetic oligosacharides mimicking the lipopolysa ...
Voir le projet
20
Participants partenaires
TERMINÉ
Vaccine Design and Immune Responses (VADER)
Date du début: 1 oct. 2012, Date de fin: 30 sept. 2016,
The successful development of new vaccines depends on the interaction of industrial expertise for vaccine design and engineering with academic understanding of the mechanisms of protection afforded by the immune responses they elicit. Close interaction between both sectors expedites vaccine development and, in the context of global health, this can translate to the saving of thousands of lives. Th ...
Voir le projet
2
Participants partenaires
TERMINÉ
Genome-driven vaccine development for bacterial infections (GENDRIVAX)
Date du début: 1 janv. 2011, Date de fin: 31 déc. 2014,
The aim of the GENDRIVAX (GENome-DRIVen Vaccine) scientific programme is to develop novel prophylactic vaccines against invasive bacterial diseases caused by Salmonella and Neisseria. GENDRIVAX intends to combine the results of recent industrial research (novel platform technologies for producing highly affordable outer membrane antigen based vaccines for Gram-negative bacteria) with the detailed ...
Voir le projet